Sacituzumab Earns Regular FDA Approval for TNBC - NCI

Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.

Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic

Pharmaceutics, Free Full-Text

Alexis Johnson on LinkedIn: So grateful to be presenting one of my

Full article: Recent progress in antibody-based therapeutics for

Antibody–Drug Conjugates for the Treatment of Breast Cancer

Recent advances in targeted strategies for triple-negative breast

Breaking barriers in triple negative breast cancer (TNBC

Sacituzumab Earns Regular FDA Approval For TNBC NCI

Recent advances in targeted strategies for triple-negative breast

FDA Approves Sacituzumab Govitecan for Triple-Negative Breast

Pharmaceutics, Free Full-Text

New FDA Alert Warns of Drug Combination for Advanced Triple-Negative Breast Cancer Patients